文献速递肾移植肾小球疾病

肾移植患者使用免疫检查点抑制剂的系统评价

Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients.
PubMed 文献 · Kidney Int Rep · 2019-12-07

结论提示肾移植患者使用免疫检查点抑制剂后急性排斥/移植物衰竭风险增加,尤其PD-1抑制剂。

要点

  • 肾移植患者使用免疫检查点抑制剂后急性排斥发生率较高,中位24天。
  • 排斥后移植物衰竭和死亡风险高,需密切监测肾功能。
  • PD-1抑制剂相关排斥风险尤其值得关注。

核心结论

  • 肾移植患者接受免疫检查点抑制剂治疗后急性移植物排斥/衰竭风险增加,尤其PD-1抑制剂。

主要发现

  • 44例肾移植患者中18例报告急性排斥,中位时间24天(四分位距10-60天)。
  • 排斥类型:细胞性33%,混合细胞与抗体介导17%,未指定50%。
  • 肿瘤结局:3例部分缓解(17%),1例肿瘤缓解(6%),5例疾病稳定(28%)。

临床怎么用

  • 肾移植患者使用免疫检查点抑制剂前应评估排斥风险,治疗期间密切监测移植肾功能。

局限性

  • 证据基于个案报告和小样本研究,需大规模临床研究进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Kidney transplant (Ktx) recipients are excluded from clinical trials of immune checkpoint inhibitors. The aim of this systematic review was to assess the safety of immune checkpoint inhibitors among Ktx patients. METHODS: A literature search was conducted using MEDLINE, EMBASE, and Cochrane Database from inception through April 2019. We included studies that reported outcomes of Ktx recipients who received immune checkpoint inhibitors for cancer treatment. Outcomes of interest were allograft rejection and/or allograft failure. RESULTS: Twenty-seven articles with a total of 44 Ktx patients treated with immune checkpoint inhibitor were identified. Of 44 Ktx patients, 18 were reported to have acute rejection. Median time from immune checkpoint inhibitors to acute rejection diagnosis was 24 (interquartile range, 10-60) days. Reported types of acute allograft rejection were cellular rejection (33%), mixed cellular and antibody-mediated rejection (17%), and unspecified type (50%). Fifteen (83%) had allograft failure and 8 (44%) died. Three patients had a partial remission (17%), 1 patient achieved cancer response (6%), and 5 patients had stable disease (28%). CONCLUSION: The findings of our study raise awareness of the increased risk for acute allograft rejection/failure following immune checkpoint inhibitors for cancer treatment among Ktx patients, in particular with programmed cell death 1 (PD-1) inhibitors. Future large-scale clinical studies are required to appraise the pathogenesis and plan optimal balanced therapy that helps sustain graft tolerance.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Manohar S, Thongprayoon C, Cheungpasitporn W, et al. Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients. Kidney Int Rep. 2019. PMID: 32043028. doi:10.1016/j.ekir.2019.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。